当前位置: 首页 >> 检索结果
1601. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
作者: Thierry André.;Elena Elez.;Heinz-Josef Lenz.;Lars Henrik Jensen.;Yann Touchefeu.;Eric Van Cutsem.;Rocio Garcia-Carbonero.;David Tougeron.;Guillermo Ariel Mendez.;Michael Schenker.;Christelle de la Fouchardiere.;Maria Luisa Limon.;Takayuki Yoshino.;Jin Li.;Jose Luis Manzano Mozo.;Laetitia Dahan.;Giampaolo Tortora.;Myriam Chalabi.;Eray Goekkurt.;Maria Ignez Braghiroli.;Rohit Joshi.;Timucin Cil.;Francine Aubin.;Elvis Cela.;Tian Chen.;Ming Lei.;Lixian Jin.;Steven I Blum.;Sara Lonardi.
来源: Lancet. 2025年405卷10476期383-395页
CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free survival with nivolumab plus ipilimumab compared with nivolumab alone, regardless of previous systemic treatment for metastatic disease. In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis for the other primary endpoint of progression-free survival for nivolumab plus ipilimumab versus nivolumab across all treatment lines.
1607. Life expectancy losses in the Gaza Strip during the period October, 2023, to September, 2024.
作者: Michel Guillot.;Mohammed Draidi.;Valeria Cetorelli.;José H C Monteiro Da Silva.;Ismail Lubbad.
来源: Lancet. 2025年405卷10477期478-485页
In the context of the ongoing war in the Gaza Strip, the Gaza Health Ministry (GHM) has reported 45 936 fatalities and more than 10 000 individuals missing or under the rubble for the period Oct 7, 2023, to Jan 8, 2025. The scope of this death count is difficult to fully interpret because it does not account for the size and age distribution of the Gaza Strip population. Moreover, the quality of this death count has been questioned. In this study, we evaluated the quality of the GHM death count by comparing GHM data against register data, and we estimated life expectancy losses in the Gaza Strip for the period October, 2023, to September, 2024, ie, the first 12 months of the war.
1608. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
作者: Michelle C Williams.;Ryan Wereski.;Christopher Tuck.;Philip D Adamson.;Anoop S V Shah.;Edwin J R van Beek.;Giles Roditi.;Colin Berry.;Nicholas Boon.;Marcus Flather.;Steff Lewis.;John Norrie.;Adam D Timmis.;Nicholas L Mills.;Marc R Dweck.;David E Newby.; .
来源: Lancet. 2025年405卷10475期329-337页
The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in management and outcomes.
1609. Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
作者: Lisa Mumford.;Rachel Hogg.;Adam Taylor.;Peter Lanyon.;Mary Bythell.;Sean McPhail.;Joseph Chilcot.;Gillian Powter.;Graham S Cooke.;Helen Ward.;Helen Thomas.;Stephen P McAdoo.;Liz Lightstone.;Sean H Lim.;Gavin J Pettigrew.;Fiona A Pearce.;Michelle Willicombe.
来源: Lancet. 2025年405卷10475期314-328页
In the UK, booster COVID-19 vaccinations have been recommended biannually to people considered immune vulnerable. We investigated, at a population level, whether the absence of detectable anti-SARS-CoV-2 spike protein IgG antibody (anti-S Ab) following three or more vaccinations in immunosuppressed individuals was associated with greater risks of infection and severity of infection.
1610. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
作者: Nisha R Acharya.;Athimalaipet V Ramanan.;Alison B Coyne.;Kathryn L Dudum.;Elia M Rubio.;Sydney M Woods.;Catherine M Guly.;Elena Moraitis.;Harry J D Petrushkin.;Kate Armon.;Narman Puvanachandra.;Jessy T Choi.;Daniel P Hawley.;Benjamin F Arnold.; .
来源: Lancet. 2025年405卷10475期303-313页
Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.
|